Literature DB >> 27810167

Comparative clinical outcomes after thymectomy for myasthenia gravis: Thoracoscopic versus trans-sternal approach.

Sophon Siwachat1, Apichat Tantraworasin2, Worakitti Lapisatepun1, Chidchanok Ruengorn3, Emanuela Taioli4, Somcharoen Saeteng1.   

Abstract

BACKGROUND: Thymectomy is an effective treatment option for long-term remission of myasthenia gravis. The superiority of the trans-sternal and thoracoscopic surgical approaches is still being debated. The aims of this study are to compare postoperative outcomes and neurologic outcomes between the two approaches and to identify prognostic factors for complete stable remission (CSR).
METHODS: Myasthenia gravis patients who underwent thymectomy with trans-sternal or thoracoscopic approach in MahaRaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand between January1, 2006 and December 31, 2013 were retrospectively reviewed. The endpoints were postoperative outcomes and cumulative incidence function for CSR. The analysis was performed using multilevel model, Cox's proportional hazard model, and propensity score.
RESULTS: Ninety-eight patients were enrolled in this study: 53 in the thoracoscopic group and 45 in the trans-sternal group. There were no significant differences between groups in composite postoperative complications, surgical time, ventilator support days, and length of intensive care unit stay. Intraoperative blood loss and length of hospital stay were significant less in the thoracoscopic group. The CSR and median time to remission were not significantly different between the two approaches. Prognostic factors for CSR were nonthymoma (hazard ratio: 3.5, 95% confidence interval: 1.01-12.22) and presence of pharmacological remission (hazard ratio: 24.3, 95% confidence interval: 3.27-180.41).
CONCLUSION: Thoracoscopic thymectomy is safe and provides good neurologic outcomes in comparison to the trans-sternal approach. Two predictive factors should be considered for CSR. Further prospective studies with a larger sample size and longer follow-up period are warranted to confirm these results.
Copyright © 2016. Published by Elsevier Taiwan.

Entities:  

Keywords:  VATS thymectomy; complete stable remission; cumulative incidence function; neurologic outcomes; pharmacologic remission

Mesh:

Year:  2016        PMID: 27810167     DOI: 10.1016/j.asjsur.2016.09.006

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  7 in total

1.  VATS thymectomy for early stage thymoma and myasthenia gravis: combined right-sided uniportal and left-sided three-portal approach.

Authors:  Maurizio Infante; Cristiano Benato; Riccardo Giovannetti; Cinzia Bonadiman; Barbara Canneto; Giovanni Falezza; Alessandro Lonardoni; Paola Gandini
Journal:  J Vis Surg       Date:  2017-10-18

2.  Thymectomy for myasthenia gravis: what's next?

Authors:  Marc de Perrot; Laura Donahoe
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

Review 3.  A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature.

Authors:  Maria Elena Farrugia; John A Goodfellow
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

4.  Video-assisted thoracic surgery for thymoma: long-term follow-up results and prognostic factors-single-center experience of 150 cases.

Authors:  Jian-Feng Li; Ben-Gang Hui; Xiao Li; Rong-Xin Xiao; Guan-Chao Jiang; Jun Liu; Jun Wang
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Clinical outcome of thymectomy in myasthenia gravis patients: A report from Iran.

Authors:  Benyamin Seyfari; Farzad Fatehi; Abolfazl Shojaiefard; Mehdi Jafari; Ali Ghorbani-Abdehgah; Shirzad Nasiri; Aidin Yaghoobi-Notash; Behnam Molavi; Amir Hossein Latif; Reza Eslamian; Ali Mir; Ahmadreza Soroush
Journal:  Iran J Neurol       Date:  2018-01-05

6.  Comparative study of video-assisted thoracoscopic surgery versus open thymectomy for thymoma and myasthenia gravis.

Authors:  Ezel Erşen; Burcu Kılıç; Hasan Volkan Kara; Mehlika İşcan; İsmail Sarbay; Ahmet Demirkaya; Selim Bakan; Melih Tütüncü; Akif Turna; Kamil Kaynak
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-05-16       Impact factor: 1.195

Review 7.  New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.

Authors:  Anthony Behin; Rozen Le Panse
Journal:  J Neuromuscul Dis       Date:  2018
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.